[ad_1]
Chinese biopharmaceutical company Sinovac has said it has doubled the annual production capacity of its Covid-19 vaccine called CoronaVac to two billion doses.
According to the company, this was made possible by the completion of its third production line which was used for commercial production.
CoronaVac is one of four domestic vaccines that have received conditional approval from Chinese authorities. It has also been cleared by national regulators in countries like Chile, Brazil and Turkey, while other countries including Ukraine and Uruguay have pre-ordered doses.
Experts from the World Health Organization said on Wednesday that an interim analysis of clinical trial data from Sinovac’s Covid-19 vaccine showed it demonstrated “safety and good efficacy”, although that more data is still needed.
The health agency’s strategic advisory group of experts on immunization said the vaccine had yet to receive clearance from what WHO considers “a strict regulatory authority.”
Sinovac is among Chinese companies that have submitted data in applications for inclusion in the WHO emergency use list, which opens the vaccine to part of the global Covax program.
The two-dose vaccine is based on the technique of injecting the deactivated coronavirus in order to trigger an immune response.
According to Sinovac, more than 200 million doses of its Covid-19 vaccine have been delivered to more than 20 countries and more than 100 million doses of CoronaVac have been administered during the vaccination rollout in different countries.
(with AFP)
Source link
